Provenance Record

Clear, well-structured News piece (622 words, within the 400-1200 News range). Overview/What We Know/What We Don't Know/Analysis structure cleanly separates the regulatory fact, the trial evidence, and the speculative outlook. Appropriate technical depth on the cefepime-zidebactam mechanism without overstating it.

All 3 source snapshots read from disk and verified; uncompressed sha256 of each matches manifest.json exactly. source-0.html.gz (PR Newswire / Wockhardt release, status 200) — verbatim-confirms the FDA indication and susceptible-microorganism list (E. coli, K. pneumoniae, P. mirabilis, E. cloacae complex, P. aeruginosa), the PBP 1a/b,2,3 multi-target mechanism quote, the metallo-beta-lactamase (MBL) activity quote, the Khorakiwala 'first New Chemical Entity ... Indian pharmaceutical company' quote, the Deruelle 'escalating crisis' quote, the DCGI approval on May 27 2026, and the pending EMA MAA. source-1.html.gz (PMC/NCBI, ENHANCE-1 OFID primary publication, status 200) — verbatim-confirms EVERY trial specific cited: '529 patients randomized and treated (352 in ZID-FEP and 177 in meropenem arms)', '417 included in the mMITT population', '44 global sites across U.S., EU, India, Mexico, and China', '2:1' randomization, 'ZID-FEP 1+ 2 g (1 h infusion) or meropenem 1 g (0.5 h infusion) for 7 to 10 days', '89.0% ... versus 68.4% ... treatment difference 20.6%; 95% CI, 12.3 to 29.5', 'statistically superior', and the subgroup list (cUTI vs AP, older adults, renal-insufficiency, obese, cefepime-resistant uropathogens). source-2.html.gz (Oxford Academic / OFID, status 200, archive_fallback) — the Archive.org snapshot captured only the Wayback Machine wrapper plus a 302 crawl-prevention redirect, not the abstract body, so it does not independently corroborate the figures; this is a snapshot limitation, not an article fault. The identical figures are fully verified in the PMC snapshot (source-1), which hosts the same OFID abstract.

Rule 9 / 5i satisfied: all ENHANCE-1 trial specifics are cited to and verified against the primary publication (PMC/OUP), not the press release. Note the press release itself states a different trial framing ('530 patients ... 64 sites') than the primary publication ('529 ... 44 sites'); the article correctly uses the primary-publication figures and attributes them to the PMC abstract, avoiding the looser PR numbers. No exact FDA action day is asserted: the article uses 'has announced' (the PR Newswire dateline reads 'June 1, 2026', but outlets disagreed and the article wisely hedges). The dropped facts noted in the brief ('over 600,000 hospitalizations' and the Keith Kaye quote) are genuinely ABSENT from the article; both in fact appear in the allowlisted PR Newswire release, so their omission is purely editorial and not a Rule 2 problem. Spelling verified verbatim (Rule 7): 'Zaynich', 'cefepime', 'zidebactam', 'ENHANCE-1', 'Wockhardt', 'meropenem'.

APPROVE. Every clinical specific traces to a cited source; the ENHANCE-1 numbers trace to the primary publication (PMC) per Rule 9/5i, all direct quotes are verbatim, the FDA action date is appropriately hedged, and key terms are spelled correctly. High-quality, fully sourced clinical submission ready for publication.